Genetic Studies of Schizophrenia and Bipolar Disorder
Abstract
Since the early 20th century, both schizophrenia (SZ) and bipolar disorder (BP) have been observed to run in families. This link was conclusively determined to be at least in part genetic in a number of twin and/or adoption studies. With the introduction of genetic polymorphisms, the identification of these factors accelerated. Dozens of whole-genome linkage studies clearly implicated a few genomic regions in each disorder, such as 13q, 8q, and 6q in BP and 5q, 6p, and 8p in SZ. Even then, debates about their etiological relationship followed findings of shared linkage regions. Since 2002, genes such as DTNBP1, NRG1, and G72/G30 have been identified in schizophrenia samples in regions of linkage and subsequently replicated in independent samples, including some BP samples. Since 2007, whole-genome association studies have been performed in ever larger samples. These have led to some novel and subsequently replicated findings such as ZNF804A markers associated in both disorders, the identification of widespread association in the major histocompatibility complex, and genome-wide correlation in small-effect polygenic variation between them. The identification of numerous copy number variants on a genome-wide scale in independent samples highlighted commonalities between SZ and developmental and learning disorders. Although the overlap in genetic findings between BP and SZ is incontrovertible, it remains to be established whether this is due to the presence of a single underlying genetic signature manifesting as a clinically variable phenotype (i.e., a unitary psychosis model). The impact of psychotic BP in many BP samples on overlap findings has not been fully investigated. A change in nosological conventions based on these data is premature, and careful examination of clinical subtypes in large samples could be informative. At the current time, large-scale sequencing and investigations of epigenetic factors, gene-gene, and gene-environment interactions, and other sources of complexity are in very early stages but are likely to contribute substantially in the future.
Schizophrenia (SZ) is marked by positive, negative, and disorganization symptoms (1) as defined in DSM-IV-TR. The defining characteristics of bipolar disorder (BP) in DSM-IV-TR are episodes of depression alternating with mania and/or hypomania positive (psychotic) symptoms and thought disorder are also common. Schizoaffective disorder and BP with psychotic features share characteristics of both disorders, as they may include mood and psychotic symptoms in varying degrees of admixture. Both are potentially severe neuropsychiatric conditions, the etiology of which is poorly understood. Genetic studies may be particularly fruitful endeavors in such conditions, as the underlying etiology might be illuminated by a detailed knowledge of risk alleles. Furthermore, both disorders are diagnosed solely on the basis of behavioral signs and symptoms as neither currently has a specific, clearly defined, pathophysiological foundation on which to base diagnostic tests. Because genetic studies inherently examine biological markers, they may provide clues in the development of such tests, which may be clinically useful in risk prediction.
The distinction between SZ and BP is generally credited to Emil Kraepelin, who distinguished dementia praecox from manic-depressive illness on the basis of course of illness (2). He observed the former, which we now refer to as SZ, as having a chronic, deteriorating course, whereas the latter, now called BP disorder, had a relapsing-remitting course. These two illnesses have generally been thought to be genetically distinct, as numerous epidemiological studies failed to convincingly demonstrate familial coaggregation until very recently. Their etiological distinctness has been further supported by the fact that antipsychotics and mood stabilizers are the mainstays of the treatment of SZ (3) and BP (4), respectively, although both drugs of both classes are often used to varying degrees in the course of both conditions. However, recent studies have strongly suggested significant commonalities in their genetic underpinnings. Furthermore, both disorders are associated with less severe manifestations segregating in family members, suggesting a spectrum phenomenon. Unipolar depression occurs more frequently in relatives of BP probands (5). In SZ, family members have an increased risk of delusional disorder, as well as schizotypal, paranoid, schizoid, and avoidant personality disorders (6–9), whereas clinically unaffected relatives have increased levels of schizotypal traits (e.g., magical thinking, odd speech, and odd behavior) (10). These findings taken together suggest that current systems of operationalized criteria for categorical disease traits may not adequately reflect their underlying genetic architecture. This hypothesis has been widely recognized and is informing present debate in the development of DSM-5 (11).
Genetic studies in general have proceeded separately for each illness. Only in the last few years has it been feasible to examine the genetic overlap of these two illnesses. Two main factors have contributed to this. First, major technological advances have made it possible to genotype more than a million markers using GeneChips or DNA microarrays. This ability has allowed unprecedented sensitivity in detecting allelic association signals on a genome-wide basis. Second, informatics, database, and web-based applications have matured greatly. Sharing very large data sets within and across countries or continents has become routine, allowing individual samples to be combined into ever larger pooled data sets, with a concomitant considerable increase in statistical power. In this article, the current status of genetics studies of both disorders will be reviewed. Particular attention will be paid to studies of their genetic relationship.
FAMILY, TWIN, AND ADOPTION STUDIES
Family studies test whether the family members of affected probands have an increased risk of the disorder compared with the general population. Whereas establishing an increased risk suggests that genetic factors are etiologically relevant, familial aggregation of illness can also be caused by environmental factors affecting sibships or even whole families. Adoption studies can separate the family environment from genetic causes by establishing differences in risk between adoptive and biological relatives (12). Twin studies exploit the fact that monozygotic twins share 100% of their DNA sequences, whereas dizygotic twins share only 50% on average (13). This 2:1 ratio of genetic resemblance makes it possible to calculate the proportion of risk to any trait or disorder that is due to genetic factors. This proportion is known as the heritability, often called h2. It is also possible to calculate c2, the proportion of risk due to environmental factors shared by family members (e.g., nutrition, parenting, socioeconomic status, infectious agents, and others).
Schizophrenia
A recent family study in Sweden examined approximately 9 million subjects in approximately 2 million families using national registries (14). First-degree relatives of individuals with SZ had an approximately ninefold increase in risk compared with that of the general population, confirming the findings of previous studies. Adopted-off offspring of schizophrenic mothers have an elevated risk of SZ compared with adopted-off offspring of control subjects (15). Furthermore, schizophrenic adoptees have been found to more frequently have schizophrenic relatives than do control adoptees (7, 16). A number of twin studies have been performed in SZ (17). Individually, there has been very little evidence of the importance of common environmental factors. However, a meta-analysis of 14 twin studies from 6 countries has demonstrated a heritability of 81%, as well as a significant common environmental component of 11% (17). This fact may have gone undetected in individual studies due to insufficient power and suggests that it may be possible to identify risk factors in the family environment and develop interventions against them, which was further supported in the Swedish population study (13).
Bipolar disorder
The risk of BP in first-degree relatives of BP probands approaches 10-fold that of the general population (5). This fact has been confirmed in the recent large Swedish population study as well (14). Twin studies indicate that the heritability of BP is high, estimated at 80–90% (18, 19). Twin studies do not support the importance of common environment, but the Swedish population study does (14). Although the risk of major depressive disorder in relatives of BP probands is increased, there is evidence of nonshared genetic factors for mania and depression (19). Adoption studies in BP have largely been underpowered (18).
LINKAGE STUDIES
Linkage is defined as the presence of two or more loci on the same chromosome. By testing for cosegregation within families of diseases and alleles of specific marker loci of known location, the probability of a disease gene being on the same chromosome as (i.e., linked to) that marker can be calculated. Levels of significance have been based on the likelihood of linkage versus the likelihood of nonlinkage, called the logarithm of the odds (lod) score (20). Linkage studies of mendelian traits have demonstrated a high degree of sensitivity and accuracy in localizing genomic regions harboring susceptibility genes, often leading to the identification of the genes themselves, as in the case of Huntington's disease (21). Linkage studies in complex traits in general and psychiatric disorders in particular have been hampered by low power and probable genetic heterogeneity (22). Numerous linkage studies have been published in BP and SZ (23–26). These have led to a number of reports of suggestive linkage, defined as a lod score expected once per genome scan (27). However, there has been a disappointing level of replication in independent samples, as well as relatively few findings of significant linkage, defined as a lod score expected once per 20 genome scans (27). These results have been attributed to low power or the presence of different risk genes in different populations (i.e., genetic heterogeneity). Another limitation of linkage studies is their low spatial resolution (28). Regions of linkage to a trait can be tens of millions of markers (megabases) in length and display considerable stochastic variation in locations of maximum linkage (29). Such limitations make identifying linkage the first step in a long process in gene discovery. Despite these limitations and the apparent eclipse of linkage studies by genome-wide association studies (GWASs), which can examine common alleles only, linkage studies may still have a role in identifying genomic regions harboring rare alleles that may have an effect in one or a few families.
Schizophrenia
More than two dozen genome-wide linkage studies of SZ have been published, as has been extensively reviewed (25, 30). The first meta-analysis used the multiple scan probability (MSP) method, which combines the region-specific p values of individual studies (26). The most significant regions of the genome were 8p, 13q, and 22q. The second used the genome scan meta-analysis (GSMA) method, which determines the significance of chromosomal regions based on how often they are highly ranked, across genome scans (25). The GSMA reported 2q as the most significant region, although few individual studies reported linkage there. In addition, less stringent significance criteria were met by 5q, 3p, 11q, 6p, 1q, 22q, 8p, 20q, and 14p (25).
Bipolar disorder
More than 20 genome-wide linkage scans have been conducted in BP, the vast majority in European ancestry populations. As with SZ, no chromosomal region has been uniformly supported across all scans, and significant linkage has been reported rarely. Regions that have been supported in several independent samples have included 1q, 4q, 6q, 8p, 8q, 10q, 11p, 12q, 13q, 18p-q, 21q, and 22q (24). Three meta-analyses have been published. As with SZ, the MSP (26) and GSMA (24) methods have been used. However, unlike in SZ, a more powerful method, that of pooling marker data (PMD), has also been used (23). In this method, genetic marker data from multiple studies are pooled and analyzed de novo using a sex-averaged marker map. In the PMD meta-analysis, a model-free lod score of 4.19 was obtained at chromosome 6q22. The 6q region had previously demonstrated significant linkage in two individual studies (31, 32). Chromosome 8q was the only other region demonstrating significant linkage in the PMD analysis.
ASSOCIATION STUDIES
Association studies are based on allele frequency differences between case patients and control subjects. Association studies have a much higher spatial resolution than linkage studies and can implicate specific risk genes or alleles. Furthermore, association is more powerful than linkage (33). Candidate gene studies select markers in specific genes for association analysis based on a priori evidence of involvement of biological systems containing such genes in the etiopathogenesis of a given disorder. Candidate gene selection is difficult in neuropsychiatric disorders because etiopathogenesis is poorly understood. However, a number of hypotheses have been generated and tested in the last several decades, such as the neurodevelopmental (34) and dopamine (35) hypotheses of SZ, as well as the monamine (36), neuroendocrine (37), and more recently, the cellular signaling and plasticity hypotheses of BP and other mood disorders (38, 39).
In more recent years, significant progress has been made in positional cloning, or association mapping, approaches. These studies usually begin with regions linked to the disorder using genome-wide linkage surveys, which use a few hundred microsatellite markers. Additional markers, including single nucleotide polymorphisms, are typed to allow for greater spatial resolution of the linkage “signal” in a process called “fine mapping.” An increasing density of markers within the linked region makes it possible to test specific genes for association. This, when combined with confirmatory approaches of such association in independent samples, expression studies, or other types of in vitro functional studies (40, 41), allows for the identification of specific risk genes or alleles. Such genes may suggest novel neurobiological pathways that may themselves become candidate etiopathogenic mechanisms.
Hundreds of association studies have been published in the last two decades. Hence, our coverage in this review will necessarily be selective. The most promising candidates, which have been supported by numerous replicated studies and/or meta-analyses, are discussed. No association studies have yet reported a sequence variant that is directly causal, i.e., either causing an amino acid substitution, frameshift, or expression change that directly results in a biological defect that can explain the symptoms of the illness. It is noteworthy that GWASs (reviewed below), which generally use denser genotyping per gene than candidate gene studies, have not supported previously associated candidate genes. They have, rather, pointed to previously unsuspected genes and intergenic regions.
SCHIZOPHRENIA
More than 900 genes have been tested in SZ in worldwide samples (42). The majority, however, have been in populations of European and East Asian ancestry. The candidate gene approach in SZ has not met with much success. The first genes identified using positional cloning have been in the 6p and 8p linkage regions. Dystrobrevin-binding protein 1 (DTNBP1) (43) and neuregulin-1 (NRG1) (40) were identified in the Irish and Icelandic populations, respectively, in 2002. Since then, they have been tested and replicated in numerous other samples (44, 45). However, the pattern of replication has been complicated by frequent failures to replicate. Furthermore, there has been an inconsistent pattern of associated alleles and haplotypes across samples in different populations. This has seldom been studied in depth. However, a recent meta-analysis of 32 studies of DTNBP1 indicated the presence of distinct association subpopulations that were not obviously explained by ethnicity (44). More thorough investigation into the causes of heterogeneity will necessitate denser genotyping of samples in which association has been observed.
Several other genes have been identified in regions of linkage and subsequently replicated in multiple samples. Regulator of G-protein signaling 4 (RGS4) (46, 47) and NRG1 (45) have both been supported by meta-analyses of associated haplotypes, but not individual SNPs. G72/G30 has been supported by a meta-analysis examining individual SNPs in both European ancestry and Asian populations (48). A meta-analysis of nine central European samples demonstrated relatively homogeneous association in 10 SNPs in disrupted in schizophrenia 1 (DISC1) (49). Although not discovered using association mapping, DISC1 occurs in the 1q42 region, which has been linked to SZ in several samples (50, 51). This gene has been supported not only by replicated association, but also by neurobiological studies. It is an interacting partner with PDE4B, which, along with DISC1 itself, is involved in cAMP signaling (52). Animal models of DISC1 underexpression are associated with brain structural abnormalities and concomitant behavioral deficits suggestive of aspects of the SZ and/or BP phenotypes (53, 54). A number of other genes have received support as well, including Akt1 (55, 56) and catechol-O-methyltranferase (COMT) (57, 58). The status of studies of these genes, including functional studies, has been recently reviewed (59).
Bipolar disorder
A number of SZ susceptibility genes have also been associated in BP. The strength of the evidence, however, is generally not as strong as that in SZ. For example, a meta-analysis of markers in the gene for G72/G30, which was initially identified in SZ and subsequently replicated in both disorders, was significant in SZ, but not in BP (48). This finding may have been due to power differences, as the sample size of SZ subjects was severalfold that for BP subjects. DISC1 (60, 61) and NRG1 (62, 63) have both been associated in more than one independent sample. However, consistent associations of alleles and haplotypes have been as elusive as in SZ. Meta-analyses have yet to be published for these genes, and they have received little support in GWASs.
A number of genes have been studied because of their function in pathways involved in biological systems thought to mediate mood symptoms. These include monoamine oxidase A (MAOA), which is involved in the degradation of biogenic amines, such as neurotransmitters. Very few individual studies have reported significant association, but a meta-analysis reported association with a CA repeat polymorphism (64). The serotonin transporter (SERT) is one of the main targets of antidepressant medications and is therefore a natural candidate gene for mood disorders. A 44-bp insertion/deletion in the promoter region (5HTTLPR), thought to alter transcription levels, has been supported in two of three meta-analyses (65, 66). The dopamine type 2 receptor (DRD2) has been studied in multiple samples, because of its blockade by antipsychotic medications. A multicenter European study reported significant association in the 5-repeat allele of a CA repeat, which has been the most studied marker in this gene (67). A number of other genes have been tested, as discussed comprehensively elsewhere, but results have shown moderate or inconsistent levels of association (68). These include DTNBP1, TPH, DRD4, and BDNF.
GENOME-WIDE ASSOCIATION STUDIES
GWASs of numerous disorders have been published. The National Human Genome Research Institute GWAS catalog (http://www.genome.gov/26525384#1) lists 583 publications as of June 14, 2010. The objective of these studies is to survey the entire genome, in the most systematic and unbiased way possible, for specific alleles associated with a disease (69). They have most commonly been performed in case-control samples, in which allele frequencies in case patients are compared with those of control subjects, much as in other association studies. However, family-based methods, examining the transmission of alleles from parents to affected offspring, may also be used. To cover as much of the entire genome as possible, approximately 1 million SNP markers are used across all chromosomes, including the X, Y, and mitochondrial chromosomes. This unprecedented density of markers is possible using GeneChips, the most recently developed of which are the Affymetrix 6.0 and Illumina 1M chips, which can genotype 906,000 and 1,199,187 SNPs, respectively. Although there are many times more SNPs in the genome, because of the correlation of SNPs close to each other (called linkage disequilibrium) (70), it is possible to detect association signals throughout the genome with only a subset of existing SNPs.
Because of the extremely large number of markers tested in a typical GWAS, the problem of multiple testing is a daunting one. An early and influential benchmark has been p<1×10−5 and p<5×10−7 as moderately strong and strong evidence for association, respectively, as suggested and used by the Wellcome Trust Case Control Consortium (WTCCC) (71). Naturally, such stringent significance thresholds necessitate samples of much greater power than in previous association studies. Such sample sizes have been made possible by combining samples from multiple sites. Nevertheless, achievement of these criteria has been rare. Many studies report not only those markers that meet criteria, but also clusters of markers, which individually have lower statistical significance but may index regions that could be pathologically relevant. The review below is necessarily selective, as numerous regions or markers are often reported in any given study and discussion of all of these is beyond the scope of this article. An attempt has been made to emphasize regions/genes with high levels of clustering (i.e., numerous associated markers close to each other), biological significance, or both.
Schizophrenia
A total of seven GWASs of SZ have been published to date. The first, in a sample of 178 case patients and 144 control subjects, reported a SNP near colony stimulating factor 2 receptor alpha chain (CSF2RA), which is in the pseudoautosomal region of the X and Y chromosomes (72). A study based on pooled DNAs observed association in the reelin (RELN) gene, which was specific to females, in an Ashkenazi Jewish sample. This was replicated in three European and one Chinese sample. RELN is known to be involved in corticogenesis, and a mutation is associated with lissencephaly in humans (73). The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, one of the largest studies of antipsychotic efficacy ever performed, also contained a genetic substudy (74). This sample formed the basis of a GWAS of SZ, which reported no SNPs with genome-wide significance. However, it may be much more informative as a genetic study of treatment response and adverse effects. In a U.K. sample, a zinc finger protein gene of unknown function (ZNF804A) was identified and then subsequently replicated in two independent replication samples which included European, Ashkenazi, Chinese, and Japanese subsamples (75). In 2009, three large GWASs of SZ performed in three independent consortia were published in the same issue of Nature (76–78). The International Schizophrenia Consortium (ISC) combined samples from several sites in the United Kingdom, Ireland, Bulgaria, Sweden, and Portugal, comprising 3,322 case patients and 3,587 control subjects (76). Significant association was observed at a marker in the major histocompatibility complex (MHC) region, very close to NOTCH4. However, 450 SNPs were associated to a lesser degree throughout the MHC region. The two other GWASs were in the Genetic Analysis Information Network (GAIN), a multicenter U.S. and Australian sample (77), and S-GENE, a European consortium (78). Neither of these two samples yielded genome-wide significant markers on its own. However, each of the groups shared at least some of their data with the other two, allowing for an unprecedentedly large meta-analysis of 8,008 case patients and 19,057 control subjects. This resulted in multiple SNPs in the MHC region meeting the criteria for genome-wide significance, as well as additional significant SNPs in or near neurogranin (11q24.2), involved in N-methyl-d-aspartate signaling, and TCF4 (18q21.2), which is essential to normal brain development. The ISC study further described a novel method in which subjects are “scored” for the number of risk alleles they carry. This method is used to test whether a set of markers only nominally associated in one sample can predict the risk of illness in a second, independent GWAS sample. Furthermore, the illness in the second sample may be the same as or different from that tested in the initial sample. With this method, the authors found evidence of the effects of possibly thousands of SNPs, supporting the long-held polygenic theory of SZ. They also observed significant genetic overlap between SZ and BP, using the WTCCC and Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) samples (covered below). Such overlap was not seen in a range of nonpsychiatric disorders, such as type II diabetes and hypertension, which were also studied in the WTCCC. This result suggested that the genetic risk to both disorders resulting from common polymorphisms was shared and that this was not due to an artifact of the DNA microarray or statistical methods used.
Bipolar disorder
To date, six GWASs using individual genotyping have been published, as well as one using pooled genotypes. The first study, the WTCCC, used 1,900 case patients and 3,000 control subjects (71). The latter were shared among GWASs of other disorders as well. It reported a SNP on 16p12 near the genes PALB2, DNUFAB1, and DCTN5. The latter interacts with DISC1. The second study combined the DNA of 461 case patients and 562 control subjects into 50–80 sample pools and used a German sample of 772 case patients and 876 control subjects for replication (79). Several markers were associated in the diacylglycerol eta (DKGH) gene, which is part of the lithium-sensitive phosphatidyl inositol pathway, and is located in chromosome 13q14, which has been linked to BP (26). The third combined a London sample with that of STEP-BD, a longitudinal U.S. cohort study assessing treatment response in BP, as well as replication samples from the United States and Scotland (80). This is often referred to as the STEP-UCL study. Haplotype analyses of SNPs in MYO5B were significant genome-wide. This gene is involved in vesicle trafficking. Other genes that were implicated in this study included TSPAN8 and EGFR. This study was followed by one that added additional samples from Edinburgh, Scotland, Dublin, Ireland, and another STEP-BD subset to the original STEP-UCL sample (81). The latter study resulted in association of ANK3, which regulates voltage-gated sodium channels in axons, as well as confirmation of CACNA1C, which had previously showed suggestive associations in the WTCCC and STEP-UCL studies. This class of calcium channels mediates a number of processes in neurons. Interestingly, calcium channel blockers have been considered a possible treatment for BPs, although their use for this indication is probably now rare. The fifth study was also funded by the GAIN network, and included samples of both European American (EA) (1,001 case patients and 1,033 control subjects) and African American (AA) subjects (345 case patients and 670 control subjects) (82). With use of haplotype analysis, it reported evidence consistent with ANK3 harboring risk variants. However, it failed to support CACNA1C. For the EA sample, the most associated SNP was in an intergenic region of chromosome Xq27.1. In the AA sample, the most associated SNP was in the DPY19L3 gene at 19q13.11. Several regions that contained clusters of SNPs with low p values (p<1×10−4) were also observed. Of these, the NAP5 gene was associated in the EA and the NTRK2 gene in the AA sample. The latter is a tyrosine kinase receptor that binds to brain-derived neurotrophic factor (BDNF), an important neurotrophin. Haplotype analysis also implicated SLITRK2, which is known to regulate neurite outgrowth. The seventh and most recent GWAS of BP was conducted in a combined sample from the National Institute of Mental Health and Prechter repositories as well as GlaxoSmithKline along with the WTCCC (83). The strongest association in the combined sample of 3,683 case patients and 14,507 control subjects was in an intron in the gene MCTP1, which binds Ca2+. Other regions containing clusters of strongly associated SNPs included 1p31.1, 3p21, and 5q15. Several of the genes located in associated regions were noted to have effects on neural development and plasticity.
STUDIES OF COPY NUMBER VARIATION
Cytogenetic studies examine the structure of chromosomes to determine whether chromosomal segments have either been deleted or enlarged or have changed location. One of the most prominent among such findings has been a deletion on chromosome 22q11 known to cause velocardiofacial syndrome. In addition to the learning disability, palatal defects, and craniofacial abnormalities seen in this syndrome, about one-third of patients have psychiatric conditions, including SZ (84) and autism (85). This region contains genes that have been associated with SZ, including COMT and PRODH (59). Another seminal finding involved the discovery of DISC1. This gene, along with DISC2, is disrupted in a balanced translocation between chromosomes 1 and 11. The translocation was discovered in a Scottish family that segregated SZ, BP, and major depressive disorder (86).
Duplications are increases in the number of times a repetitive DNA segment occurs. Deletions, on the other hand, are decrements in the number of times such a segment occurs. Together, these are called copy number variants (CNVs). One of the benefits of DNA microarrays used in GWASs is that they not only allow the simultaneous genotyping of approximately 1 million SNPs, they also can be used to infer copy number using the intensity values observed for individual SNPs. For example, four copies of a given allele will have greater intensity than two copies, and so on. This same technology has therefore led to a rapid increase in studies of both common SNPs and rare CNVs. Other technologies, such as array-comparative genomic hybridization may also be used. The last several years have witnessed a significant proliferation of CNV studies in both BP and SZ. One study group, the ISC, has published genome-wide association (76) and CNV studies (87) using the same DNA microarray data. Up to now there have been considerably more CNV studies in SZ than in BP. As with GWASs, these studies of necessity use very large sample sizes but for different reasons. Because individual CNVs can be quite rare, e.g., they may appear only a few times in several thousand subjects, the effect sizes must therefore be large to be detectable, which had previously been very rarely observed in psychiatric genetics.
Schizophrenia
A number of studies have reported that patients with SZ have a greater number of CNVs (i.e., CNV burden) than control subjects (87, 88–90). Interestingly, the CNVs that had the largest effect were present in genes and also were the rarest CNVs, occurring in only one individual (i.e., singletons). Pathway analyses of genes containing CNVs demonstrated an enrichment if genes were involved in synaptic transmission or neurodevelopment (90). Several specific deletions and duplications have been found to be recurrent, i.e., occurred in several individuals. Some of these have now been replicated in independent samples. As with GWASs, the earlier genome-wide CNV studies included at most a few hundred case patients and control subjects but were able to detect significant differences in CNV burden between the groups.
In 2008, two comparatively very large studies were published in the same issue of Nature (86, 88). These two identified the 1q21.1 deletion. It was rare, at 0.2% in control subjects, and had an odds ratio (OR) of 9.1. A combined analysis of these two samples, the ISC and Steffanson et al. studies (86, 88), along with a Cardiff sample, strongly supported a deletion at 15q13.3 (91). It was rare in schizophrenic patients, at 0.2% frequency, but more than 10-fold rarer in control subjects, yielding an OR of 11.4. This deletion has been found in non-SZ samples as well, where it has been associated with variable phenotypes including intellectual dysfunction, autism, and attention deficit/hyperactivity disorder (92). Recently, evidence for a deletion at 16p11.2 was reported in a meta-analysis to have an OR of 8.4 (93). This deletion has also been found in autism and intellectual disability (94). In addition to larger CNVs deleting one or more genes, some CNVs may be smaller and may only disrupt a single gene. One prominent example is in neurexin 1 (NRXN1), which along with other neurexins, induces postsynaptic differentiation in dendrites. Several independent groups have identified SZ-related CNVs in this gene (90, 95, 96). One study examined 2,977 case patients and 22,746 control subjects from seven European populations, focusing specifically on the neurexins. Patients with SZ were much more likely to have exonic CNVs in NRXN1 than control subjects (0.24%–0.015%, OR=9) (97). The common finding that SZ-related CNVs are also associated with other developmental or behavioral disorders has driven hypotheses about their variable expressivity. For example, it may be possible that environmental, epigenetic, or stochastic factors can shape the form and outcome of a neuropsychiatric condition once a pathway has been interrupted by a specific CNV (98).
Bipolar disorder
The GAIN BP sample was analyzed for singleton deletions and duplications (i.e., those that appear only once in a data set) (99). Although no significant differences in number of duplications were found in patients with BP, the number of singleton deletions was enriched in case patients versus control subjects (0.18 versus 0.13, p=0.01). When only those with onsets at age 18 or younger were included in analysis, the proportion of case patients with deletions was even greater. Using Ingenuity Pathways Analysis software, the authors observed that genes disrupted in case patients, compared with those in control subjects, were overrepresented in pathways important to “psychological disorders and behaviors such as learning” (99).
EVIDENCE OF GENETIC OVERLAP
Family studies have been used to determine whether the relatives of patients with SZ have an increased risk of BP and vice versa. Several studies have found an increased risk of psychotic BP in the relatives of SZ probands, but a number of studies have failed to find such familial coaggregation of SZ and BP in general (100, 101). Recently, a record linkage study in Sweden examined more than 2 million families merged in a multigenerational population registry with a national hospital discharge registry, which contained information on specific diagnoses (14). Significant familial coaggregation of these two disorders was observed. The authors were able to use the information available on family relationships (e.g., sibling versus half-sibling, parent, and others) to estimate the heritabilities of both disorders. Furthermore, they estimated the proportion of risk attributable to genetic factors common to both at 63%. This influential study of unprecedented size suggested that previous studies examining familial coaggregation of SZ and BP were underpowered to detect a true phenomenon.
Some chromosomal regions have been implicated in linkage studies of both disorders. Among these are 13q (26). Interestingly, one of the genes in this region, G72/G30, has also been associated with both disorders (48). Schulze et al. (102) reported that markers in this gene were associated with a subset of a German bipolar sample who had persecutory delusions. This finding was replicated in a Polish sample and suggested that the genetic overlap between BP and SZ may in part be mediated by psychotic symptoms common to both. A number of other genes have also been implicated in both disorders, such as NRG1 and DISC1, as discussed above in “Association Studies.”
GWASs have provided an unprecedented opportunity to investigate the genetic overlap between disorders on a genome-wide scale. Evidence for association in a GWAS in a U.K. SZ sample for ZNF804A increased when BP was added to SZ in the phenotype definition (75). A similar pattern was observed in an independent sample (103). Whereas twin studies can indicate genetic correlation between disorders, they can only infer the aggregate additive genetic effects using the correlations between relatives, such as monozygotic and dizygotic twins. Twin studies, furthermore, rest on the equal environment assumption, which posits that common environmental sharing is the same magnitude in monozygotic as in dizygotic twins, but this theory has not always been supported in all disorders (104). GWASs, on the other hand, can use the actual marker data in cohorts of unrelated subjects, allowing specific genomic regions causing overlap to be identified. Recently, the ISC described a novel method to test for genetic overlap between phenotypes using GWAS data. They reported that the observed polygenic risk for SZ was substantially shared with that for BP, using two independent BP GWAS samples, STEP-BD and WTCCC (76).
Discussion of the nosological implications of genetic overlap has accelerated since early reports of association of BP with genes discovered in SZ, most notably G72/G30 (105, 106). These findings, in conjunction with the convergence of findings in SZ and BP from the realms of structural and functional imaging, neuropathology, neuropsychology, and psychophysiology [reviewed by Maier et al. (107)] have led to debates about the usefulness of the “Kraepelinian dichotomy.” A widely accepted set of criteria put forth by Robins and Guze (108) to support the validity of any given illness included family inheritance and biological markers (of which sequence variants are a subset). These two criteria suggest that a “unitary psychosis” model (109) may “carve nature at its joints” more meaningfully than the Kraepelinian dichotomy. However, clinical course is another validating criterion, and one in which SZ and BP differ considerably. Furthermore, differential response to treatment, as clearly seen in BP and SZ, has also been posited to be a distinguishing factor (110). Therefore, despite the overlapping genetic findings reviewed in this article, important discontinuities between BP and SZ remain difficult to ignore or explain away. Moreover, the reliance on genetics as an arbitrating factor in nosological distinctions is limited by the increasing complexity and plasticity of our concept of the gene as a discrete entity, as argued by Kendler (111).
SUBTYPES OF ILLNESS
Both BP and SZ are known to be clinically heterogeneous even in their full-blown forms. BPs may have psychotic, euphoric, mixed, and rapid cycling presentations, and puerperal onset, as well as comorbid panic disorder and obsessive-compulsive disorder (112). SZ has disorganized, catatonic, and paranoid subtypes (DSM-IV-TR), as well as clinically and genetically relevant presentations such as deficit syndrome (113). The remarkable variability in the clinical presentation of SZ has prompted debate over whether it is one or more disorders since the time of Eugen Bleuler (114). Both disorders can have early or late age of onset, good and poor course and outcome, and the presence of suicidality and substance abuse, not to mention symptomatic dimensions such as psychosis, thought disorder, and others. Many of these illness variables demonstrate heritability, suggesting that they may reflect genetic subtypes (115, 116). If latent genetic subtypes are in fact expressed as clinical subtypes, use of clinically nonspecific illness definitions (such as traditional SZ and BP operationalized criteria) may decrease the signal to noise ratio in gene-finding studies.
Schizophrenia
Even before Kraepelin's seminal dichotomy between dementia praecox and manic-depressive illness, a number of more specific clinical presentations were described. These included hebephrenia, paranoia, and catatonia (117). Although they are still seen as DSM subtypes (118), their etiological relationship with operationally defined SZ has been unclear. A number of investigations have suggested the presence of genes that affect more or less distinct illness subtypes. Family studies demonstrate that several symptomatic dimensions, as well as subtypes, aggregate within families (115). Twin studies of symptom dimensions or subtypes require samples of concordant monozygotic and dizygotic twin pairs (compared with twin studies of SZ, which examined both concordant and discordant pairs). The resulting smaller sample sizes and low power have made it difficult to draw conclusions from twin studies of such phenotypes.
A number of association studies have tested for allelic effects on symptom dimensions in SZ-only samples. Although these have been too few and underpowered to be conclusive, some interesting patterns have emerged. For example, DTNBP1 has been shown to be preferentially associated with negative symptoms in two independent samples (119, 120). It was also associated with a more progressive illness course (121) and cognitive decline (122) as well as low levels of manic symptoms (123), which may correlate with negative symptoms, and with reduced occipital and prefrontal brain volumes (124) and greater spatial working memory deficits (125). These findings taken together suggest that DTNBP1 variants may be risk factors for a more chronic, deficit-like clinical picture with more negative symptoms, cognitive deficits, and brain structural abnormalities, reminiscent of Crow's type II syndrome (126). Additional findings have included associations between DISC1 and delusions, Akt1 and hallucinations (56), and TAAR6 and delusions (127). Two independent samples reported association between COMT and affective symptoms (128, 129). Interestingly, these were the same two samples that reported associations between DTNBP1 and negative symptoms. Although these studies provide interesting leads, the general lack of replication and small sample sizes make it difficult to draw firm conclusions. However, studies of quantitative symptom dimensions and subtypes may critically inform nosological debate. In fact, the shift toward a more quantitative approach to diagnosis is one of the key components of the development of DSM-5 (11).
Several linkage studies have used illness subtypes as the phenotype of interest to reduce clinical heterogeneity. These have mostly used phenotypes based on empirical (i.e., statistical) subtyping methods, such as latent class analysis. Results include linkage of SZ with cognitive deficit to 6p24 (130), the latent classes “mania” and “schizomania” to 20p (131), and a latent class resembling deficit SZ to 1q23–25 (132). The finding of little or no linkage in these regions to traditional phenotype definitions suggests that genetic heterogeneity across clinical subtypes may contribute to negative findings. Testing of empirical subtypes and quantitative symptomatic dimensions in GWAS and other studies may therefore help clarify the pattern of findings across samples. This is planned as part of the Psychiatric GWAS Consortium (PGC) (133).
Bipolar disorder
The presentation of BP has been noted to be variable even since the adoption of Kraepelin's dichotomy, when manic-depressive illness subsumed the more contemporary concepts of major depressive disorder and BP with psychotic features (2). A number of illness variables, including subtypes, have been delineated. The one that has received by far the most attention in genetic studies is BP with psychotic features (psychotic BP). These findings have been reviewed in detail (112). A number of linkage studies have been performed using psychotic BP as the phenotype of interest. Interestingly, some of these have yielded linkage signals in chromosomal regions that have been linked to SZ in several independent samples. These have included 5q33-q34 (134) and 8p21-p22 (135). Chromosome 13q31-33 has been linked to both SZ and BP and has also resulted in linkage to psychotic BP (134–136). Although 2p11-q14 has not been linked to SZ in many individual samples, meta-analysis of 20 SZ samples showed it to be the most highly linked region of the genome (25). A study of psychotic BP with mood-incongruent psychotic features reported linkage to this region (136). A number of SZ candidate genes have also been associated with psychotic BP, such as DTNBP1 (137), and G72/G30 (102), as mentioned above. Although not a SZ candidate gene, GRIA1 is in the 5q linkage region of SZ and has been associated with psychotic BP (138). The number of significant findings in psychotic BP and SZ raises the question of whether the observed genetic overlap of SZ and BP (14, 76) is explained by that between SZ and psychotic BP specifically. A number of other putative subtypes and quantitative traits remain to be tested in informative samples. This may be facilitated by the Bipolar Phenome Database (139), which aims to catalog phenotypic data on numerous BP samples. Work proposed in the PGC, which has a Cross-Disorders Group, may also shed light on a number of BP phenotypes as well as their genetic overlap with SZ and other disorders (133).
NEW DIRECTIONS: PERIPHERAL GENE EXPRESSION, EPIGENETICS, AND DEEP SEQUENCING
The studies reviewed heretofore involve the examination of known sequence variants and their impact on the clinical phenotype. These approaches may not be as sensitive to other kinds of genomic alterations, necessitating the development of new avenues of inquiry. Epigenetic changes are heritable modifications to the genome that do not involve sequence changes. For example, an addition of a methyl group to a cytosine residue can decrease expression by reducing binding of transcription factors. Methylation is mediated by DNA methyltransferase (DNMT1), the expression of which is up-regulated in brain tissue in both BP and SZ (140). Intriguingly, some antipsychotics and mood stabilizers may decrease methylation, which may explain a portion of their mechanism of action (141). This has recently been observed in peripheral blood lymphocytes as well (142).
Genome-wide gene expression in peripheral blood lymphocytes has been a primary focus in several studies. Although sequence variants are assumed to alter either protein function or expression, these studies examined RNA transcript levels directly. One of the criticisms of these studies is based on the assumption that the brain is the only organ relevant to the vulnerability to psychiatric illness. However, the recent strong implication of the MHC region, including several human leukocyte antigen genes, suggests that genetically mediated dysfunction of cell types in the immune system may affect risk as well. There have been few such studies, and replication has not been attempted yet, but expression changes in genes involved in myelination and growth factor signaling in mood disorders (143), as well as myelination, synaptic function, (144), and glutamate metabolism (145) in SZ.
Finally, a method that has long been practiced but that will assume increasing prominence is DNA sequencing. Studies using known markers, as reviewed above, may miss true causative variants, some of which may be rare, because they may not correlate with unobserved variations in regions of low linkage disequilibrium. Recent technological developments, such as the Illumina/Solexa, Roche/454, and SOLiD 3 systems have allowed for unprecedented throughput, orders of magnitude greater than traditional Sanger sequencing (146). This has made it practical to sequence whole chromosomal regions and exomes, and, in the future, whole genomes of patients and control subjects, which will be facilitated by publicly available whole genome sequences such as the 1000 Genomes Project (http://www.1000genomes.org/page.php).
CONCLUSIONS
After many years of meager success, genetic studies of SZ and BP have borne considerable fruit in the last decade. Much of this has been due to the success of the Human Genome Project's rapid discovery and dissemination of genomic information. Technological advances have made it possible to cheaply and rapidly measure up to a million genotypes, which has led to numerous discoveries of both genomic regions likely to harbor susceptibility genes, as well as a plethora of individual putative susceptibility genes. Although the majority of these have failed to be replicated, a small but significant number are very unlikely to be false-positives. Examples of both common and rare variants are of particular interest. The first are common SNPs in genes such as ZNF804A, MHC genes, and CACNA1C, which have been discovered in GWASs and replicated in additional independent samples with a high level of statistical significance. The second are rare CNVs, such as the deletions in 1q21.1 and 15q13.3, which have been independently confirmed in large samples. The genome-wide consistency of small-effect alleles across large independent samples is also striking (76), especially given the rigorous effort to eliminate artifacts.
Intriguingly, in all of these examples, the effect of alleles has an impact on both SZ and BP. The association of ZNF804A in both SZ and BP supports the genetic overlap of these disorders strongly suggested by a large GWAS (76) and family studies (14). However, a true understanding of the causes of such phenotypic overlap is limited by our diagnostic system, especially as used in genetic studies. BP studies tend to “lump” bipolar I disorder with and without psychosis, along with schizoaffective disorder, bipolar type. It is therefore possible that the latter two entities are genetic subtypes of a putative psychotic spectrum and are in fact driving the observed genetic overlap. These questions can only be resolved by examining large, phenotypically homogenous subtypes, such as BP with and without psychosis, and SZ with and without affective symptoms. This examination may now be possible in the largest consortia such as the PGC. It is therefore too soon to use genetic data to declare the demise of the Kraepelinian dichotomy, especially because there are other reasons not to. It could be more helpful to use the wealth of genetic information currently available to attempt to explain the seemingly infinite variation observed in the mood and psychotic disorders. Doing so may also speed gene discovery by decreasing homogeneity.
Perhaps more a more pressing issue than the knowledge that has already been gained involves the massive remaining gaps in our knowledge base. The allelic heterogeneity of susceptibility genes is a conundrum, especially given the large numbers of studies reporting association (e.g., with DTNBP1). Rather than eschew the evidence for such genes, it would be wise to continue to probe for an underlying explanation for the observed associations using deep sequencing and other modalities. GWAS signals also need to be probed to isolate nearby causative variants. Finally, there are a number of other factors that remain to be accounted for in explaining the impact of genetic variation on risk. These include environmental variables, gene-gene interactions, gene-environment interactions, the interaction between sequence and epigenetic variation, and the presence of very rare alleles and CNVs, which may not be detected using current technology. Some of these factors have been invoked in explaining the “missing heritability” of complex disease, and increasing attention should be paid to them (147).
REFERENCES
1.
Peralta V, Cuesta MJ: How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment. Schizophr Res 2001; 49: 269– 285
2.
Kraepelin E: Manic-Depressive Illness and Paranoia. Edinburgh, Scotland, E & S Livingstone, 1921
3.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209– 1223
4.
Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, Nierenberg AA, Fava M, Bowden C, Ketter T, Marangell L, Calabrese J, Kupfer D, Rosenbaum JF: Rationale, design, and methods of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry 2003; 53: 1028– 1042
5.
Tsuang, Faraone SV. The Genetics of Mood Disorders. Baltimore, Johns Hopkins University Press, 1990
6.
Asarnow RF, Nuechterlein KH, Fogelson D, Subotnik KL, Payne DA, Russell AT, Asamen J, Kuppinger H, Kendler KS: Schizophrenia and schizophrenia-spectrum personality disorders in the first-degree relatives of children with schizophrenia: the UCLA family study. Arch Gen Psychiatry 2001; 58: 581– 588
7.
Baron M, Gruen R, Rainer JD, Kane J, Asnis L, Lord S: A family study of schizophrenic and normal control probands: implications for the spectrum concept of schizophrenia. Am J Psychiatry 1985; 142: 447– 455
8.
Kendler KS, Gruenberg AM, Kinney DK: Independent diagnoses of adoptees and relatives as defined by DSM-III in the provincial and national samples of the Danish Adoption Study of Schizophrenia. Arch Gen Psychiatry 1994; 51: 456– 468
9.
Kendler KS, McGuire M, Gruenberg AM, O'Hare A, Spellman M, Walsh D: The Roscommon Family Study. III. Schizophrenia-related personality disorders in relatives. Arch Gen Psychiatry 1993; 50: 781– 788
10.
Kendler KS, McGuire M, Gruenberg AM, Walsh D: Schizotypal symptoms and signs in the Roscommon Family Study. Their factor structure and familial relationship with psychotic and affective disorders. Arch Gen Psychiatry 1995; 52: 296– 303
11.
Regier DA, Narrow WE, Kuhl EA, Kupfer DJ: The conceptual development of DSM-V. Am J Psychiatry 2009; 166: 645– 650
12.
Ingraham LJ, Kety SS: Adoption studies of schizophrenia. Am J Med Genet 2000; 97: 18– 22
13.
Neale M, Cardon LR: Methodology for Genetic Studies of Twins and Families. Dordrecht, The Netherlands, Kluwer Academic, 1992
14.
Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM: Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009; 373: 234– 239
15.
Heston LL: Psychiatric disorders in foster home reared children of schizophrenic mothers. Br J Psychiatry 1966; 112: 819– 825
16.
Kety SS, Rosenthal D, Wender PH, Schulsinger F: Mental illness in the biological and adoptive families of adpoted schizophrenics. Am J Psychiatry 1971; 128: 302– 306
17.
Sullivan PF, Kendler KS, Neale MC: Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003; 60: 1187– 1192
18.
Smoller JW, Finn CT: Family, twin, and adoption studies of bipolar disorder. Am J Med Genet C Semin Med Genet 2003; 123C: 48– 58
19.
McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A: The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 2003; 60: 497– 502
20.
Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES: Parametric and nonparametric linkage analysis: a unified multipoint approach. Am J Hum Genet 1996; 58: 1347– 1363
21.
Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, Watkins PC, Ottina K, Wallace MR, Sakaguchi AY. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983; 306: 234– 238
22.
Risch N: Genetic linkage and complex diseases, with special reference to psychiatric disorders. Genet Epidemiol 1990; 7: 3– 16; discussion 17–45
23.
McQueen MB, Devlin B, Faraone SV, Nimgaonkar VL, Sklar P, Smoller JW, Abou Jamra R, Albus M, Bacanu SA, Baron M, Barrett TB, Berrettini W, Blacker D, Byerley W, Cichon S, Coryell W, Craddock N, Daly MJ, Depaulo JR, Edenberg HJ, Foroud T, Gill M, Gilliam TC, Hamshere M, Jones I, Jones L, Juo SH, Kelsoe JR, Lambert D, Lange C, Lerer B, Liu J, Maier W, Mackinnon JD, McInnis MG, McMahon FJ, Murphy DL, Nothen MM, Nurnberger JI, Pato CN, Pato MT, Potash JB, Propping P, Pulver AE, Rice JP, Rietschel M, Scheftner W, Schumacher J, Segurado R, Van Steen K, Xie W, Zandi PP, Laird NM: Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. Am J Hum Genet 2005; 77: 582– 595
24.
Segurado R, Detera-Wadleigh SD, Levinson DF, Lewis CM, Gill M, Nurnberger JI Jr, Craddock N, DePaulo JR, Baron M, Gershon ES, Ekholm J, Cichon S, Turecki G, Claes S, Kelsoe JR, Schofield PR, Badenhop RF, Morissette J, Coon H, Blackwood D, McInnes LA, Foroud T, Edenberg HJ, Reich T, Rice JP, Goate A, McInnis MG, McMahon FJ, Badner JA, Goldin LR, Bennett P, Willour VL, Zandi PP, Liu J, Gilliam C, Juo SH, Berrettini WH, Yoshikawa T, Peltonen L, Lönnqvist J, Nöthen MM, Schumacher J, Windemuth C, Rietschel M, Propping P, Maier W, Alda M, Grof P, Rouleau GA, Del-Favero J, Van Broeckhoven C, Mendlewicz J, Adolfsson R, Spence MA, Luebbert H, Adams LJ, Donald JA, Mitchell PB, Barden N, Shink E, Byerley W, Muir W, Visscher PM, Macgregor S, Gurling H, Kalsi G, McQuillin A, Escamilla MA, Reus VI, Leon P, Freimer NB, Ewald H, Kruse TA, Mors O, Radhakrishna U, Blouin JL, Antonarakis SE, Akarsu N: Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: bipolar disorder. Am J Hum Genet 2003; 73: 49– 62
25.
Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, Williams NM, Schwab SG, Pulver AE, Faraone SV, Brzustowicz LM, Kaufmann CA, Garver DL, Gurling HM, Lindholm E, Coon H, Moises HW, Byerley W, Shaw SH, Mesen A, Sherrington R, O'Neill FA, Walsh D, Kendler KS, Ekelund J, Paunio T, Lönnqvist J, Peltonen L, O'Donovan MC, Owen MJ, Wildenauer DB, Maier W, Nestadt G, Blouin JL, Antonarakis SE, Mowry BJ, Silverman JM, Crowe RR, Cloninger CR, Tsuang MT, Malaspina D, Harkavy-Friedman JM, Svrakic DM, Bassett AS, Holcomb J, Kalsi G, McQuillin A, Brynjolfson J, Sigmundsson T, Petursson H, Jazin E, Zoëga T, Helgason T: Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet 2003; 73: 34– 48
26.
Badner JA, Gershon ES: Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 2002; 7: 405– 411
27.
Lander E, Kruglyak L: Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 1995; 11: 241– 247
28.
Riley BP, McGuffin P: Linkage and associated studies of schizophrenia. Am J Med Genet 2000; 97: 23– 44
29.
Roberts SB, MacLean CJ, Neale MC, Eaves LJ, Kendler KS: Replication of linkage studies of complex traits: an examination of variation in location estimates. Am J Hum Genet 1999; 65: 876– 884
30.
Riley B, Kendler KS: Molecular genetic studies of schizophrenia. Eur J Hum Genet 2006; 14: 669– 680
31.
Dick DM, Foroud T, Flury L, Bowman ES, Miller MJ, Rau NL, Moe PR, Samavedy N, El-Mallakh R, Manji H, Glitz DA, Meyer ET, Smiley C, Hahn R, Widmark C, McKinney R, Sutton L, Ballas C, Grice D, Berrettini W, Byerley W, Coryell W, DePaulo R, MacKinnon DF, Gershon ES, Kelsoe JR, McMahon FJ, McInnis M, Murphy DL, Reich T, Scheftner W, Nurnberger JI Jr: Genomewide linkage analysis of bipolar disorder: a new sample of 250 pedigrees from the National Institute of Mental Health Genetics Initiative. Am J Hum Genet 2003; 73: 107– 114
32.
Middleton FA, Pato MT, Gentile KL, Morley CP, Zhao X, Eisener AF, Brown A, Petryshen TL, Kirby AN, Medeiros H, Carvalho C, Macedo A, Dourado A, Coelho I, Valente J, Soares MJ, Ferreira CP, Lei M, Azevedo MH, Kennedy JL, Daly MJ, Sklar P, Pato CN: Genomewide linkage analysis of bipolar disorder by use of a high-density single-nucleotide-polymorphism (SNP) genotyping assay: a comparison with microsatellite marker assays and finding of significant linkage to chromosome 6q22. Am J Hum Genet 2004; 74: 886– 897
33.
Risch N, Merikangas K: The future of genetic studies of complex human diseases. Science 1996; 273: 1516– 1517
34.
Weinberger DR: Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987; 44: 660– 669
35.
Davis KL, Kahn RS, Ko G, Davidson M: Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148: 1474– 1486
36.
Charney DS: Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998; 59( Suppl 14): 11– 14
37.
Daban C, Vieta E, Mackin P, Young AH: Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am 2005; 28: 469– 480
38.
Schloesser RJ, Huang J, Klein PS, Manji HK: Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 2008; 33: 110– 133
39.
Shaltiel G, Chen G, Manji HK: Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol 2007; 7: 22– 26
40.
Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson K: Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 71: 877– 892
41.
Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H, Bougueleret L, Barry C, Tanaka H, La Rosa P, Puech A, Tahri N, Cohen-Akenine A, Delabrosse S, Lissarrague S, Picard FP, Maurice K, Essioux L, Millasseau P, Grel P, Debailleul V, Simon AM, Caterina D, Dufaure I, Malekzadeh K, Belova M, Luan JJ, Bouillot M, Sambucy JL, Primas G, Saumier M, Boubkiri N, Martin-Saumier S, Nasroune M, Peixoto H, Delaye A, Pinchot V, Bastucci M, Guillou S, Chevillon M, Sainz-Fuertes R, Meguenni S, Aurich-Costa J, Cherif D, Gimalac A, Van Duijn C, Gauvreau D, Ouellette G, Fortier I, Raelson J, Sherbatich T, Riazanskaia N, Rogaev E, Raeymaekers P, Aerssens J, Konings F, Luyten W, Macciardi F, Sham PC, Straub RE, Weinberger DR, Cohen N, Cohen D, Ouelette G, Realson J. Rosa P, Puech A, Tahri N, Cohen-Akenine A, Delabrosse S, Lissarrague S, Picard FP, Maurice K, Essioux L, Millasseau P, Grel P, Debailleul V, Simon AM, Caterina D, Dufaure I, Malekzadeh K, Belova M, Luan JJ, Bouillot M, Sambucy JL, Primas G, Saumier M, Boubkiri N, Martin-Saumier S, Nasroune M, Peixoto H, Delaye A, Pinchot V, Bastucci M, Guillou S, Chevillon M, Sainz-Fuertes R, Meguenni S, Aurich-Costa J, Cherif D, Gimalac A, Van Duijn C, Gauvreau D, Ouellette G, Fortier I, Raelson J, Sherbatich T, Riazanskaia N, Rogaev E, Raeymaekers P, Aerssens J, Konings F, Luyten W, Macciardi F, Sham PC, Straub RE, Weinberger DR, Cohen N, Cohen D, Ouelette G, Realson J: Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 2002; 99: 13675– 13680
42.
Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ, Tanzi RE, Bertram L: Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008; 40: 827– 834
43.
Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV, Harris-Kerr C, Wormley B, Sadek H, Kadambi B, Cesare AJ, Gibberman A, Wang X, O'Neill FA, Walsh D, Kendler KS: Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 2002; 71: 337– 348
44.
Maher BS, Reimers MA, Riley BP, Kendler KS: Allelic heterogeneity in genetic association meta-analysis: an application to DTNBP1 and schizophrenia. Hum Hered 2010; 69: 71– 79
45.
Munafò MR, Attwood AS, Flint J: Neuregulin 1 genotype and schizophrenia. Schizophr Bull 2008; 34: 9– 12
46.
Chowdari KV, Mirnics K, Semwal P, Wood J, Lawrence E, Bhatia T, Deshpande SN, BKT, Ferrell RE, Middleton FA, Devlin B, Levitt P, Lewis DA, Nimgaonkar VL: Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 2002; 11: 1373– 1380
47.
Talkowski ME, Seltman H, Bassett AS, Brzustowicz LM, Chen X, Chowdari KV, Collier DA, Cordeiro Q, Corvin AP, Deshpande SN, Egan MF, Gill M, Kendler KS, Kirov G, Heston LL, Levitt P, Lewis DA, Li T, Mirnics K, Morris DW, Norton N, O'Donovan MC, Owen MJ, Richard C, Semwal P, Sobell JL, St Clair D, Straub RE, Thelma BK, Vallada H, Weinberger DR, Williams NM, Wood J, Zhang F, Devlin B, Nimgaonkar VL: Evaluation of a susceptibility gene for schizophrenia: genotype based meta-analysis of RGS4 polymorphisms from thirteen independent samples. Biol Psychiatry 2006; 60: 152– 162
48.
Detera-Wadleigh SD, McMahon FJ: G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol Psychiatry 2006; 60: 106– 114
49.
Schumacher J, Laje G, Abou Jamra R, Becker T, Mühleisen TW, Vasilescu C, Mattheisen M, Herms S, Hoffmann P, Hillmer AM, Georgi A, Herold C, Schulze TG, Propping P, Rietschel M, McMahon FJ, Nöthen MM, Cichon S: The DISC locus and schizophrenia: evidence from an association study in a central European sample and from a meta-analysis across different European populations. Hum Mol Genet 2009; 18: 2719– 2727
50.
Ekelund J, Hennah W, Hiekkalinna T, Parker A, Meyer J, Lönnqvist J, Peltonen L: Replication of 1q42 linkage in Finnish schizophrenia pedigrees. Mol Psychiatry 2004; 9: 1037– 1041
51.
Macgregor S, Visscher PM, Knott SA, Thomson P, Porteous DJ, Millar JK, Devon RS, Blackwood D, Muir WJ: A genome scan and follow-up study identify a bipolar disorder susceptibility locus on chromosome 1q42. Mol Psychiatry 2004; 9: 1083– 1090
52.
Camargo LM, Wang Q, Brandon NJ: What can we learn from the disrupted in schizophrenia 1 interactome: lessons for target identification and disease biology? Novartis Found Symp 2008; 289: 208– 216
53.
Ayhan Y, Abazyan B, Nomura J, Kim R, Ladenheim B, Krasnova IN, Sawa A, Margolis RL, Cadet JL, Mori S, Vogel MW, Ross CA, Pletnikov MV: Differential effects of prenatal and postnatal expressions of mutant human DISC1 on neurobehavioral phenotypes in transgenic mice: evidence for neurodevelopmental origin of major psychiatric disorders. Mol Psychiatry 2010; doi:
54.
Pletnikov MV, Ayhan Y, Nikolskaia O, Xu Y, Ovanesov MV, Huang H, Mori S, Moran TH, Ross CA: Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatry 2008; 13: 173– 186, 115
55.
Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA: Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nat Genet 2004; 36: 131– 137
56.
Thiselton DL, Vladimirov VI, Kuo PH, McClay J, Wormley B, Fanous A, O'Neill FA, Walsh D, Van den Oord EJ, Kendler KS, Riley BP: AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol Psychiatry. 2008; 63: 449– 457
57.
Chen X, Wang X, O'Neill AF, Walsh D, Kendler KS: Variants in the catechol-O-methyltransferase (COMT) gene are associated with schizophrenia in Irish high-density families. Mol Psychiatry 2004; 9: 962– 967
58.
Shifman S, Bronstein M, Sternfeld M, Pisanté A, Weizman A, Reznik I, Spivak B, Grisaru N, Karp L, Schiffer R, Kotler M, Strous RD, Swartz-Vanetik M, Knobler HY, Shinar E, Yakir B, Zak NB, Darvasi A: COMT: a common susceptibility gene in bipolar disorder and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 128B: 61– 64
59.
Schwab SG, Wildenauer DB: Update on key previously proposed candidate genes for schizophrenia. Curr Opin Psychiatry 2009; 22: 147– 153
60.
Hodgkinson CA, Goldman D, Jaeger J, Persaud S, Kane JM, Lipsky RH, Malhotra AK: Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am J Hum Genet 2004; 75: 862– 872
61.
Thomson PA, Wray NR, Millar JK, Evans KL, Hellard SL, Condie A, Muir WJ, Blackwood DH, Porteous DJ: Association between the TRAX/DISC locus and both bipolar disorder and schizophrenia in the Scottish population. Mol Psychiatry 2005; 10: 657– 668, 616
62.
Goes FS, Willour VL, Zandi PP, Belmonte PL, MacKinnon DF, Mondimore FM, Schweizer B, Gershon ES, McMahon FJ, Potash JB: Family-based association study of Neuregulin 1 with psychotic bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 693– 702
63.
Green EK, Raybould R, Macgregor S, Gordon-Smith K, Heron J, Hyde S, Grozeva D, Hamshere M, Williams N, Owen MJ, O'Donovan MC, Jones L, Jones I, Kirov G, Craddock N: Operation of the schizophrenia susceptibility gene, neuregulin 1, across traditional diagnostic boundaries to increase risk for bipolar disorder. Arch Gen Psychiatry 2005; 62: 642– 648
64.
Furlong RA, Ho L, Rubinsztein JS, Walsh C, Paykel ES, Rubinsztein DC: Analysis of the monoamine oxidase A (MAOA) gene in bipolar affective disorder by association studies, meta-analyses, and sequencing of the promoter. Am J Med Genet 1999; 88: 398– 406
65.
Lasky-Su JA, Faraone SV, Glatt SJ, Tsuang MT: Meta-analysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders. Am J Med Genet B Neuropsychiatr Genet 2005; 133B: 110– 115
66.
Cho HJ, Meira-Lima I, Cordeiro Q, Michelon L, Sham P, Vallada H, Collier DA: Population-based and family-based studies on the serotonin transporter gene polymorphisms and bipolar disorder: a systematic review and meta-analysis. Mol Psychiatry 2005; 10: 771– 781
67.
Massat I, Souery D, Del-Favero J, Van Gestel S, Serretti A, Macciardi F, Smeraldi E, Kaneva R, Adolfsson R, Nylander PO, Blackwood D, Muir W, Papadimitriou GN, Dikeos D, Oruc L, Segman RH, Ivezic S, Aschauer H, Ackenheil M, Fuchshuber S, Dam H, Jakovljevic M, Peltonen L, Hilger C, Hentges F, Staner L, Milanova V, Jazin E, Lerer B, Van Broeckhoven C, Mendlewicz J: Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European Multicenter Association Study of affective disorders. Am J Med Genet 2002; 114: 177– 185
68.
Serretti A, Mandelli L: The genetics of bipolar disorder: genome ‘hot regions,’ genes, new potential candidates and future directions. Mol Psychiatry 2008; 13: 742– 771
69.
McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, Hirschhorn JN: Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008; 9: 356– 369
70.
Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D: The structure of haplotype blocks in the human genome. Science 2002; 296: 2225– 2229
71.
Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661– 678.
72.
Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, Malhotra AK: Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry 2007; 12: 572– 580
73.
Hong SE, Shugart YY, Huang DT, Shahwan SA, Grant PE, Hourihane JO, Martin ND, Walsh CA: Autosomal recessive lissencephaly with cerebellar hypoplasia is associated with human RELN mutations. Nat Genet 2000; 26: 93– 96
74.
Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, Liu W, Downing AM, Lieberman J, Close SL: Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 2008; 13: 570– 584
75.
O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V, Nikolov I, Hamshere M, Carroll L, Georgieva L, Dwyer S, Holmans P, Marchini JL, Spencer CC, Howie B, Leung HT, Hartmann AM, Möller HJ, Morris DW, Shi Y, Feng G, Hoffmann P, Propping P, Vasilescu C, Maier W, Rietschel M, Zammit S, Schumacher J, Quinn EM, Schulze TG, Williams NM, Giegling I, Iwata N, Ikeda M, Darvasi A, Shifman S, He L, Duan J, Sanders AR, Levinson DF, Gejman PV, Cichon S, Nöthen MM, Gill M, Corvin A, Rujescu D, Kirov G, Owen MJ, Buccola NG, Mowry BJ, Freedman R, Amin F, Black DW, Silverman JM, Byerley WF, Cloninger CR: Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008; 40: 1053– 1055
76.
International Schizophrenia Consortium, Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P: Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748– 752
77.
Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I, Dudbridge F, Holmans PA, Whittemore AS, Mowry BJ, Olincy A, Amin F, Cloninger CR, Silverman JM, Buccola NG, Byerley WF, Black DW, Crowe RR, Oksenberg JR, Mirel DB, Kendler KS, Freedman R, Gejman PV: Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature. 2009; 460: 753– 757
78.
Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Børglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Böttcher Y, Olesen J, Breuer R, Möller HJ, Giegling I, Rasmussen HB, Timm S, Mattheisen M, Bitter I, Réthelyi JM, Magnusdottir BB, Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R, Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E, Kiemeney LA, Genetic Risk and Outcome in Psychosis (GROUP), Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de Frutos R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N, Toulopoulou T, Need AC, Ge D, Yoon JL, Shianna KV, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jönsson EG, Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Matthews PM, Muglia P, Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA: Common variants conferring risk of schizophrenia. Nature 2009; 460: 744– 747
79.
Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, Schulze TG, Cichon S, Rietschel M, Nöthen MM, Georgi A, Schumacher J, Schwarz M, Abou Jamra R, Höfels S, Propping P, Satagopan J, Detera-Wadleigh SD, Hardy J, McMahon FJ: A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry 2008; 13: 197– 207
80.
Sklar P, Smoller JW, Fan J, Ferreira MA, Perlis RH, Chambert K, Nimgaonkar VL, McQueen MB, Faraone SV, Kirby A, de Bakker PI, Ogdie MN, Thase ME, Sachs GS, Todd-Brown K, Gabriel SB, Sougnez C, Gates C, Blumenstiel B, Defelice M, Ardlie KG, Franklin J, Muir WJ, McGhee KA, MacIntyre DJ, McLean A, VanBeck M, McQuillin A, Bass NJ, Robinson M, Lawrence J, Anjorin A, Curtis D, Scolnick EM, Daly MJ, Blackwood DH, Gurling HM, Purcell SM: Whole-genome association study of bipolar disorder. Mol Psychiatry 2008; 13: 558– 569
81.
Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L, Fan J, Kirov G, Perlis RH, Green EK, Smoller JW, Grozeva D, Stone J, Nikolov I, Chambert K, Hamshere ML, Nimgaonkar VL, Moskvina V, Thase ME, Caesar S, Sachs GS, Franklin J, Gordon-Smith K, Ardlie KG, Gabriel SB, Fraser C, Blumenstiel B, Defelice M, Breen G, Gill M, Morris DW, Elkin A, Muir WJ, McGhee KA, Williamson R, MacIntyre DJ, MacLean AW, St CD, Robinson M, Van Beck M, Pereira AC, Kandaswamy R, McQuillin A, Collier DA, Bass NJ, Young AH, Lawrence J, Ferrier IN, Anjorin A, Farmer A, Curtis D, Scolnick EM, McGuffin P, Daly MJ, Corvin AP, Holmans PA, Blackwood DH, Gurling HM, Owen MJ, Purcell SM, Sklar P, Craddock N: Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 2008; 40: 1056– 1058
82.
Smith EN, Bloss CS, Badner JA, Barrett T, Belmonte PL, Berrettini W, Byerley W, Coryell W, Craig D, Edenberg HJ, Eskin E, Foroud T, Gershon E, Greenwood TA, Hipolito M, Koller DL, Lawson WB, Liu C, Lohoff F, McInnis MG, McMahon FJ, Mirel DB, Murray SS, Nievergelt C, Nurnberger J, Nwulia EA, Paschall J, Potash JB, Rice J, Schulze TG, Scheftner W, Panganiban C, Zaitlen N, Zandi PP, Zöllner S, Schork NJ, Kelsoe JR: Genome-wide association study of bipolar disorder in European American and African American individuals. Mol Psychiatry 2009; 14: 755– 763
83.
Scott LJ, Muglia P, Kong XQ, Guan W, Flickinger M, Upmanyu R, Tozzi F, Li JZ, Burmeister M, Absher D, Thompson RC, Francks C, Meng F, Antoniades A, Southwick AM, Schatzberg AF, Bunney WE, Barchas JD, Jones EG, Day R, Matthews K, McGuffin P, Strauss JS, Kennedy JL, Middleton L, Roses AD, Watson SJ, Vincent JB, Myers RM, Farmer AE, Akil H, Burns DK, Boehnke M: Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. Proc Natl Acad Sci U S A 2009; 106: 7501– 7506
84.
Karayiorgou M, Morris MA, Morrow B, Shprintzen RJ, Goldberg R, Borrow J, Gos A, Nestadt G, Wolyniec PS, Lasseter VK: Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci U S A 1995; 92: 7612– 7616
85.
Fine SE, Weissman A, Gerdes M, Pinto-Martin J, Zackai EH, McDonald-McGinn DM, Emanuel BS: Autism spectrum disorders and symptoms in children with molecularly confirmed 22q11.2 deletion syndrome. J Autism Dev Disord 2005; 35: 461– 470
86.
Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, Devon RS, St Clair DM, Muir WJ, Blackwood DH, Porteous DJ: Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet 2000; 9: 1415– 1423
87.
Stone JL, O'Donovan MC, Gurling H, Kirov GK, Blackwood DH, Corvin A, Craddock NJ, Gill M, Hultman CM, Lichtenstein P, McQuillin A, Pato CN, Ruderfer DM, Owen MJ, St Clair D, Sullivan PF, Sklar P, Purcell Leader SM, Stone JL, Ruderfer DM, Korn J, Kirov GK, Macgregor S, McQuillin A, Morris DW, O'Dushlaine CT, Daly MJ, Visscher PM, Holmans PA, O'Donovan MC, Sullivan PF, Sklar P, Purcell Leader SM, Gurling H, Corvin A, Blackwood DH, Craddock NJ, Gill M, Hultman CM, Kirov GK, Lichtenstein P, McQuillin A, O'Donovan MC, Owen MJ, Pato CN, Purcell SM, Scolnick EM, St Clair D, Stone JL, Sullivan PF, Sklar LP, O'Donovan MC, Kirov GK, Craddock NJ, Holmans PA, Williams NM, Georgieva L, Nikolov I, Norton N, Williams H, Toncheva D, Milanova V, Owen MJ, Hultman CM, Lichtenstein P, Thelander EF, Sullivan P, Morris DW, O'Dushlaine CT, Kenny E, Waddington JL, Gill M, Corvin A, McQuillin A, Choudhury K, Datta S, Pimm J, Thirumalai S, Puri V, Krasucki R, Lawrence J, Quested D, Bass N, Curtis D, Gurling H, Crombie C, Fraser G, Leh KS, Walker N, St Clair D, Blackwood DH, Muir WJ, McGhee KA, Pickard B, Malloy P, Maclean AW, Van Beck M, Visscher PM, Macgregor S, Pato MT, Medeiros H, Middleton F, Carvalho C, Morley C, Fanous A, Conti D, Knowles JA, Paz FC, Macedo A, Helena AM, Pato CN, Stone JL, Ruderfer DM, Korn J, McCarroll SA, Daly M, Purcell SM, Sklar P, Purcell SM, Stone JL, Chambert K, Ruderfer DM, Korn J, McCarroll SA, Gates C, Gabriel SB, Mahon S, Ardlie K, Daly MJ, Scolnick EM, Sklar P: Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 2008; 455: 237– 241
88.
Stefansson H, Rujescu D, Cichon S, Pietiläinen OP, Ingason A, Steinberg S, Fossdal R, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, Muglia P, Francks C, Matthews PM, Gylfason A, Halldorsson BV, Gudbjartsson D, Thorgeirsson TE, Sigurdsson A, Jonasdottir A, Jonasdottir A, Bjornsson A, Mattiasdottir S, Blondal T, Haraldsson M, Magnusdottir BB, Giegling I, Möller HJ, Hartmann A, Shianna KV, Ge D, Need AC, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Paunio T, Toulopoulou T, Bramon E, Di Forti M, Murray R, Ruggeri M, Vassos E, Tosato S, Walshe M, Li T, Vasilescu C, Mühleisen TW, Wang AG, Ullum H, Djurovic S, Melle I, Olesen J, Kiemeney LA, Franke B, GROUP, Sabatti C, Freimer NB, Gulcher JR, Thorsteinsdottir U, Kong A, Andreassen OA, Ophoff RA, Georgi A, Rietschel M, Werge T, Petursson H, Goldstein DB, Nöthen MM, Peltonen L, Collier DA, St Clair D, Stefansson K: Large recurrent microdeletions associated with schizophrenia. Nature 2008; 455: 232– 236
89.
Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, Karayiorgou M: Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet 2008; 40: 880– 885
90.
Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, Nord AS, Kusenda M, Malhotra D, Bhandari A, Stray SM, Rippey CF, Roccanova P, Makarov V, Lakshmi B, Findling RL, Sikich L, Stromberg T, Merriman B, Gogtay N, Butler P, Eckstrand K, Noory L, Gochman P, Long R, Chen Z, Davis S, Baker C, Eichler EE, Meltzer PS, Nelson SF, Singleton AB, Lee MK, Rapoport JL, King MC, Sebat J: Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008; 320: 539– 543
91.
Kirov G, Grozeva D, Norton N, Ivanov D, Mantripragada KK, Holmans P, Craddock N, Owen MJ, O'Donovan MC: Support for the involvement of large copy number variants in the pathogenesis of schizophrenia. Hum Mol Genet 2009; 18: 1497– 1503
92.
Ben-Shachar S, Lanpher B, German JR, Qasaymeh M, Potocki L, Nagamani SC, Franco LM, Malphrus A, Bottenfield GW, Spence JE, Amato S, Rousseau JA, Moghaddam B, Skinner C, Skinner SA, Bernes S, Armstrong N, Shinawi M, Stankiewicz P, Patel A, Cheung SW, Lupski JR, Beaudet AL, Sahoo T: Microdeletion 15q13.3: a locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders. J Med Genet 2009; 46: 382– 388
93.
McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S, Perkins DO, Dickel DE, Kusenda M, Krastoshevsky O, Krause V, Kumar RA, Grozeva D, Malhotra D, Walsh T, Zackai EH, Kaplan P, Ganesh J, Krantz ID, Spinner NB, Roccanova P, Bhandari A, Pavon K, Lakshmi B, Leotta A, Kendall J, Lee YH, Vacic V, Gary S, Iakoucheva LM, Crow TJ, Christian SL, Lieberman JA, Stroup TS, Lehtimäki T, Puura K, Haldeman-Englert C, Pearl J, Goodell M, Willour VL, Derosse P, Steele J, Kassem L, Wolff J, Chitkara N, McMahon FJ, Malhotra AK, Potash JB, Schulze TG, Nöthen MM, Cichon S, Rietschel M, Leibenluft E, Kustanovich V, Lajonchere CM, Sutcliffe JS, Skuse D, Gill M, Gallagher L, Mendell NR, Wellcome Trust Case Control Consortium, Craddock N, Owen MJ, O'Donovan MC, Shaikh TH, Susser E, Delisi LE, Sullivan PF, Deutsch CK, Rapoport J, Levy DL, King MC, Sebat J: Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet 2009; 41: 1223– 1227
94.
Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, Saemundsen E, Stefansson H, Ferreira MA, Green T, Platt OS, Ruderfer DM, Walsh CA, Altshuler D, Chakravarti A, Tanzi RE, Stefansson K, Santangelo SL, Gusella JF, Sklar P, Wu BL, Daly MJ, Autism Consortium: Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med 2008; 358: 667– 675
95.
Kirov G, Gumus D, Chen W, Norton N, Georgieva L, Sari M, O'Donovan MC, Erdogan F, Owen MJ, Ropers HH, Ullmann R: Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet 2008; 17: 458– 465
96.
Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I, Strengman E, Genetic Risk and Outcome in Psychosis (GROUP) Consortium, Sabatti C, Geurts van Kessel A, Brunner HG, Ophoff RA, Veltman JA: Recurrent CNVs disrupt three candidate genes in schizophrenia patients. Am J Hum Genet 2008; 83: 504– 510
97.
Rujescu D, Ingason A, Cichon S, Pietiläinen OP, Barnes MR, Toulopoulou T, Picchioni M, Vassos E, Ettinger U, Bramon E, Murray R, Ruggeri M, Tosato S, Bonetto C, Steinberg S, Sigurdsson E, Sigmundsson T, Petursson H, Gylfason A, Olason PI, Hardarsson G, Jonsdottir GA, Gustafsson O, Fossdal R, Giegling I, Möller HJ, Hartmann AM, Hoffmann P, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Djurovic S, Melle I, Andreassen OA, Hansen T, Werge T, Kiemeney LA, Franke B, Veltman J, Buizer-Voskamp JE, Sabatti C, Ophoff RA, Rietschel M, Nöthen MM, Stefansson K, Peltonen L, St Clair D, Stefansson H, Collier DA: Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet 2009; 18: 988– 996
98.
Sebat J, Levy DL, McCarthy SE: Rare structural variants in schizophrenia: one disorder, multiple mutations; one mutation, multiple disorders. Trends Genet 2009; 25: 528– 535
99.
Zhang D, Cheng L, Qian Y, Alliey-Rodriguez N, Kelsoe JR, Greenwood T, Nievergelt C, Barrett TB, McKinney R, Schork N, Smith EN, Bloss C, Nurnberger J, Edenberg HJ, Foroud T, Sheftner W, Lawson WB, Nwulia EA, Hipolito M, Coryell W, Rice J, Byerley W, McMahon F, Schulze TG, Berrettini W, Potash JB, Belmonte PL, Zandi PP, McInnis MG, Zöllner S, Craig D, Szelinger S, Koller D, Christian SL, Liu C, Gershon ES: Singleton deletions throughout the genome increase risk of bipolar disorder. Mol Psychiatry 2009; 14: 376– 380
100.
Kendler KS, McGuire M, Gruenberg AM, Spellman M, O'Hare A, Walsh D: The Roscommon Family Study. II. The risk of nonschizophrenic nonaffective psychoses in relatives. Arch Gen Psychiatry 1993; 50: 645– 652
101.
Erlenmeyer-Kimling L, Adamo UH, Rock D, Roberts SA, Bassett AS, Squires-Wheeler E, Cornblatt BA, Endicott J, Pape S, Gottesman II: The New York High-Risk Project. Prevalence and comorbidity of axis I disorders in offspring of schizophrenic parents at 25-year follow-up. Arch Gen Psychiatry 1997; 54: 1096– 1102
102.
Schulze TG, Ohlraun S, Czerski PM, Schumacher J, Kassem L, Deschner M, Gross M, Tullius M, Heidmann V, Kovalenko S, Jamra RA, Becker T, Leszczynska-Rodziewicz A, Hauser J, Illig T, Klopp N, Wellek S, Cichon S, Henn FA, McMahon FJ, Maier W, Propping P, Nöthen MM, Rietschel M: Genotype-phenotype studies in bipolar disorder showing association between the DAOA/G30 locus and persecutory delusions: a first step toward a molecular genetic classification of psychiatric phenotypes. Am J Psychiatry 2005; 162: 2101– 2108
103.
Steinberg S, Mors O, Borglum AD, Gustafsson O, Werge T, Mortensen PB, Andreassen OA, Sigurdsson E, Thorgeirsson TE, Bottcher Y, Olason P, Ophoff RA, Cichon S, Gudjonsdottir IH, Pietilainen OP, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Athanasiu L, Suvisaari J, Lonnqvist J, Paunio T, Hartmann A, Jurgens G, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Breuer R, Moller HJ, Giegling I, Glenthoj B, Rasmussen HB, Mattheisen M, Bitter I, Rethelyi JM, Sigmundsson T, Fossdal R, Thorsteinsdottir U, Ruggeri M, Tosato S, Strengman E, Kiemeney LA, Melle I, Djurovic S, Abramova L, Kaleda V, Walshe M, Bramon E, Vassos E, Li T, Fraser G, Walker N, Toulopoulou T, Yoon J, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Jonsson EG, Terenius L, Agartz I, Petursson H, Nothen MM, Rietschel M, Peltonen L, Rujescu D, Collier DA, Stefansson H, St Clair D, Stefansson K: Expanding the range of ZNF804A variants conferring risk of psychosis. Mol Psychiatry 2010; doi:
104.
Hettema JM, Neale MC, Kendler KS: Physical similarity and the equal-environment assumption in twin studies of psychiatric disorders. Behav Genet 1995; 25: 327– 335
105.
Craddock N, O'Donovan MC, Owen MJ: Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr Bull 2006; 32: 9– 16
106.
Owen MJ, Craddock N, Jablensky A: The genetic deconstruction of psychosis. Schizophr Bull 2007; 33: 905– 911
107.
Maier W, Höfgen B, Zobel A, Rietschel M: Genetic models of schizophrenia and bipolar disorder: overlapping inheritance or discrete genotypes? Eur Arch Psychiatry Clin Neurosci 2005; 255: 159– 166
108.
Robins E, Guze SB: Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am J Psychiatry 1970; 126: 983– 987
109.
Berrios GE: Unitary psychosis concept, in A History of Clinical Psychiatry. Edited by Berrios GE, Porter R. London, Athlone Press, 1995, pp 313– 335
110.
Kendler KS: Toward a scientific psychiatric nosology. Strengths and limitations. Arch Gen Psychiatry 1990; 47: 969– 973
111.
Kendler KS: Reflections on the relationship between psychiatric genetics and psychiatric nosology. Am J Psychiatry 2006; 163: 1138– 1146
112.
Goes FS, Sanders LL, Potash JB: The genetics of psychotic bipolar disorder. Curr Psychiatry Rep 2008; 10: 178– 189
113.
Kirkpatrick B, Ross DE, Walsh D, Karkowski L, Kendler KS: Family characteristics of deficit and nondeficit schizophrenia in the Roscommon Family Study. Schizophr Res 2000; 45: 57– 64
114.
Bleuler E: Dementia Praecox, or The Group of Schizophrenias. New York, International Universities Press, 1950
115.
Fanous AH, Kendler KS: Genetics of clinical features and subtypes of schizophrenia: a review of the recent literature. Curr Psychiatry Rep 2008; 10: 164– 170
116.
Schulze TG, Hedeker D, Zandi P, Rietschel M, McMahon FJ: What is familial about familial bipolar disorder? Resemblance among relatives across a broad spectrum of phenotypic characteristics. Arch Gen Psychiatry 2006; 63: 1368– 1376
117.
Andreasen NC, Carpenter WT Jr: Diagnosis and classification of schizophrenia. Schizophr Bull 1993; 19: 199– 214
118.
McGlashan TH, Fenton WS: Classical subtypes for schizophrenia: literature review for DSM-IV. Schizophr Bull 1991; 17: 609– 632
119.
Fanous AH, van den Oord EJ, Riley BP, Aggen SH, Neale MC, O'Neill FA, Walsh D, Kendler KS: Relationship between a high-risk haplotype in the DTNBP1 (dysbindin) gene and clinical features of schizophrenia. Am J Psychiatry 2005; 162: 1824– 1832
120.
DeRosse P, Funke B, Burdick KE, Lencz T, Ekholm JM, Kane JM, Kucherlapati R, Malhotra AK: Dysbindin genotype and negative symptoms in schizophrenia. Am J Psychiatry 2006; 163: 532– 534
121.
Tosato S, Ruggeri M, Bonetto C, Bertani M, Marrella G, Lasalvia A, Cristofalo D, Aprili G, Tansella M, Dazzan P, Diforti M, Murray RM, Collier DA: Association study of dysbindin gene with clinical and outcome measures in a representative cohort of Italian schizophrenic patients. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 647– 659
122.
Burdick KE, Lencz T, Funke B, Finn CT, Szeszko PR, Kane JM, Kucherlapati R, Malhotra AK: Genetic variation in DTNBP1 influences general cognitive ability. Hum Mol Genet 2006; 15: 1563– 1568
123.
Corvin A, Donohoe G, Nangle JM, Schwaiger S, Morris D, Gill M: A dysbindin risk haplotype associated with less severe manic-type symptoms in psychosis. Neurosci Lett 2008; 431: 146– 149
124.
Donohoe G, Frodl T, Morris D, Spoletini I, Cannon DM, Cherubini A, Caltagirone C, Bossù P, McDonald C, Gill M, Corvin AP, Spalletta G: Reduced occipital and prefrontal brain volumes in dysbindin-associated schizophrenia. Neuropsychopharmacology 2010; 35: 368– 373
125.
Donohoe G, Morris DW, Clarke S, McGhee KA, Schwaiger S, Nangle JM, Garavan H, Robertson IH, Gill M, Corvin A: Variance in neurocognitive performance is associated with dysbindin-1 in schizophrenia: a preliminary study. Neuropsychologia 2007; 45: 454– 458
126.
Crow TJ: The two-syndrome concept: origins and current status. Schizophr Bull 1985; 11: 471– 486
127.
Vladimirov V, Thiselton DL, Kuo PH, McClay J, Fanous A, Wormley B, Vittum J, Ribble R, Moher B, van den Oord E, O'Neill FA, Walsh D, Kendler KS, Riley BP: A region of 35 kb containing the trace amine associate receptor 6 (TAAR6) gene is associated with schizophrenia in the Irish study of high-density schizophrenia families. Mol Psychiatry 2007; 12: 842– 853
128.
DeRosse P, Funke B, Burdick KE, Lencz T, Goldberg TE, Kane JM, Kucherlapati R, Malhotra AK: COMT genotype and manic symptoms in schizophrenia. Schizophr Res 2006; 87: 28– 31
129.
McClay JL, Fanous A, van den Oord EJ, Webb BT, Walsh D, O'Neill FA, Kendler KS, Chen X: Catechol-O-methyltransferase and the clinical features of psychosis. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 935– 938
130.
Hallmayer JF, Kalaydjieva L, Badcock J, Dragovic M, Howell S, Michie PT, Rock D, Vile D, Williams R, Corder EH, Hollingsworth K, Jablensky A: Genetic evidence for a distinct subtype of schizophrenia characterized by pervasive cognitive deficit. Am J Hum Genet 2005; 77: 468– 476
131.
Fanous AH, Neale MC, Webb BT, Straub RE, O'Neill FA, Walsh D, Riley BP, Kendler KS: Novel linkage to chromosome 20p using latent classes of psychotic illness in 270 Irish high-density families. Biol Psychiatry 2008; 64: 121– 127
132.
Holliday EG, McLean DE, Nyholt DR, Mowry BJ: Susceptibility locus on chromosome 1q23–25 for a schizophrenia subtype resembling deficit schizophrenia identified by latent class analysis. Arch Gen Psychiatry 2009; 66: 1058– 1067
133.
Cichon S, Craddock N, Daly M, Faraone SV, Gejman PV, Kelsoe J, Lehner T, Levinson DF, Moran A, Sklar P, Sullivan PF: Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am J Psychiatry 2009; 166: 540– 556
134.
Kerner B, Brugman DL, Freimer NB: Evidence of linkage to psychosis on chromosome 5q33–34 in pedigrees ascertained for bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 74– 78
135.
Park N, Juo SH, Cheng R, Liu J, Loth JE, Lilliston B, Nee J, Grunn A, Kanyas K, Lerer B, Endicott J, Gilliam TC, Baron M: Linkage analysis of psychosis in bipolar pedigrees suggests novel putative loci for bipolar disorder and shared susceptibility with schizophrenia. Mol Psychiatry 2004; 9: 1091– 1099
136.
Goes FS, Zandi PP, Miao K, McMahon FJ, Steele J, Willour VL, Mackinnon DF, Mondimore FM, Schweizer B, Nurnberger JI Jr, Rice JP, Scheftner W, Coryell W, Berrettini WH, Kelsoe JR, Byerley W, Murphy DL, Gershon ES, Bipolar Disorder Phenome Group, Depaulo JR Jr, McInnis MG, Potash JB: Mood-incongruent psychotic features in bipolar disorder: familial aggregation and suggestive linkage to 2p11-q14 and 13q21–33. Am J Psychiatry 2007; 164: 236– 247
137.
Raybould R, Green EK, MacGregor S, Gordon-Smith K, Heron J, Hyde S, Caesar S, Nikolov I, Williams N, Jones L, O'Donovan MC, Owen MJ, Jones I, Kirov G, Craddock N: Bipolar disorder and polymorphisms in the dysbindin gene (DTNBP1). Biol Psychiatry 2005; 57: 696– 701
138.
Kerner B, Jasinska AJ, DeYoung J, Almonte M, Choi OW, Freimer NB: Polymorphisms in the GRIA1 gene region in psychotic bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 24– 32
139.
Potash JB, Toolan J, Steele J, Miller EB, Pearl J, Zandi PP, Schulze TG, Kassem L, Simpson SG, Lopez V, MacKinnon DF, McMahon FJ: The bipolar disorder phenome database: a resource for genetic studies. Am J Psychiatry 2007; 164: 1229– 1237
140.
Costa E, Dong E, Grayson DR, Guidotti A, Ruzicka W, Veldic M: Reviewing the role of DNA (cytosine-5) methyltransferase overexpression in the cortical GABAergic dysfunction associated with psychosis vulnerability. Epigenetics 2007; 2: 29– 36
141.
Guidotti A, Dong E, Kundakovic M, Satta R, Grayson DR, Costa E: Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol Sci 2009; 30: 55– 60
142.
Zhubi A, Veldic M, Puri NV, Kadriu B, Caruncho H, Loza I, Sershen H, Lajtha A, Smith RC, Guidotti A, Davis JM, Costa E: An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. Schizophr Res 2009; 111: 115– 122
143.
Le-Niculescu H, Kurian SM, Yehyawi N, Dike C, Patel SD, Edenberg HJ, Tsuang MT, Salomon DR, Nurnberger JI Jr, Niculescu AB: Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry 2009; 14: 156– 174
144.
Le-Niculescu H, Balaraman Y, Patel S, Tan J, Sidhu K, Jerome RE, Edenberg HJ, Kuczenski R, Geyer MA, Nurnberger JI Jr, Faraone SV, Tsuang MT, Niculescu AB: Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 129– 158
145.
Middleton FA, Pato CN, Gentile KL, McGann L, Brown AM, Trauzzi M, Diab H, Morley CP, Medeiros H, Macedo A, Azevedo MH, Pato MT: Gene expression analysis of peripheral blood leukocytes from discordant sib-pairs with schizophrenia and bipolar disorder reveals points of convergence between genetic and functional genomic approaches. Am J Med Genet B Neuropsychiatr Genet 2005; 136B: 12– 25
146.
Metzker ML: Sequencing technologies—the next generation. Nat Rev Genet 2010; 11: 31– 46
147.
Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM: Finding the missing heritability of complex diseases. Nature 2009; 461: 747– 753
Information & Authors
Information
Published In
History
Published online: 1 July 2010
Published in print: Summer 2010
Authors
Funding Information
CME Disclosure
Ayman H. Fanous, M.D., Washington VA Medical Center, Washington, DC, Georgetown University School of Medicine, Washington, DC, and Virginia Commonwealth University School of Medicine, Richmond, Virginia.
Dr. Fanous has received grants from NARSAD, NIMH, and the Department of Veterans Affairs Merit Review Program. Dr. Fanous reports no financial relationships with commercial interests.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).